AZD 2098

Key Product Details

Product Description

AZD 2098 is a potent and selective CCR4 antagonist (pIC₅₀ = 7.8). Exhibits no activity at CXCR1 and CXCR2, CCR1, CCR2b, CCR5, CCR7, and CCR8 at 10 μM, and no significant activity when screened against a panel of 120 receptors and enzymes. Inhibits CCL22 Ca²⁺ response and Th2 cell CCL17/22 driven chemotaxis in vitro. Inhibits lung inflammation following antigen challenge in ovalbumin- sensitized rats.

Product Specifications for AZD 2098

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for AZD 2098

The following data is based on the product molecular weight 334.18.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.99 mL	14.96 mL	29.92 mL
5 mM	0.60 mL	2.99 mL	5.98 mL
10 mM	0.30 mL	1.50 mL	2.99 mL
50 mM	0.06 mL	0.30 mL	0.60 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Kindon Discovery of AZD-2098 and AZD-1678, two potent and bioavailable CCR4 receptor antagonists. ACS Med.Chem.Lett. 2017 PMID: 28947948
• Mullard Cancer charity sees success re-prioritizing industry's shelved compounds. Nat.Rev.Drug Discov. 2014 PMID: 24781536
• Toogood Small molecule immuno-oncology therapeutic agents. Bioorg.Med.Chem.Lett. 2017 PMID: 29326017

Product Documents for AZD 2098